FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FALBERG KATHRYN E		 2. Issuer Name and Ticker or Trading Symbol

Nuvation Bio Inc. [ NUVB ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/30/2022
(Street)

NEW YORK, NY 10036
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 11/30/2022  P  75041 A$1.8535 (1)75041 I By Trust (2)
Class A Common Stock 12/1/2022  P  84959 A$1.9727 (3)160000 I By Trust (2)
Class A Common Stock 12/2/2022  P  47000 A$1.9827 (4)207000 I By Trust (2)
Class A Common Stock 12/5/2022  P  43000 A$1.9526 (4)250000 I By Trust (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.805 to $1.90. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
(2) Shares are held directly by The Falberg-Predovich Family Trust, of which the Reporting Person is Co-Trustee.
(3) Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.92 to $1.99. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
(4) Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.925 to $2.00. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
FALBERG KATHRYN E
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401
NEW YORK, NY 10036		X
Signatures
Kathryn E. Falberg, by /s/ Ron A. Metzger, Attorney-in-Fact12/5/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Panacea Acquisition (NYSE:PANA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Panacea Acquisition Charts.
Panacea Acquisition (NYSE:PANA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Panacea Acquisition Charts.